Neurotoxicity Syndromes
Symptoms, Doctors, Treatments, Advances & More

Neurotoxicity Syndromes Overview

Save information for later
Sign Up

Learn About Neurotoxicity Syndromes

What is the definition of Neurotoxicity Syndromes?
Neurotoxicity syndromes is a term used to describe neurological disorders caused by exposure to toxic substances. Neurotoxicity may occur after exposure to substances such as drugs; chemotherapy; radiation; heavy metals, such as lead or mercury; pesticides; industrial and/or cleaning solvents; petroleum-based products and dispersants; some foods and food additives; and some naturally occurring environmental substances. Exposure to such toxic substances disrupts or kills nerve cells, or neurons, that are responsible for brain and nervous system functions. Neurotoxicity may occur by exposure to toxic substances through ingestion, injection, inhalation, spray, direct skin exposure, or other methods.
What are the symptoms of Neurotoxicity Syndromes?
Symptoms of neurotoxicity may be immediate or delayed. Symptoms of neurotoxicity can include weakness, numbness, headache, memory loss, visual disturbances, cognitive difficulties, behavioral changes, and loss of sexual function, among others.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Neurotoxicity Syndromes?
Treatment for neurotoxicity includes stopping any exposure to the toxic substance and supportive therapy to treat the associated symptoms.
Who are the top Neurotoxicity Syndromes Local Doctors?
Distinguished in Neurotoxicity Syndromes
Dr. Frederick L. Locke
Internal Medicine
Distinguished in Neurotoxicity Syndromes
Dr. Frederick L. Locke
Internal Medicine

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
813-692-4252
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Frederick Locke is a primary care provider, practicing in Internal Medicine in Tampa, Florida. Dr. Locke is rated as a Distinguished provider by MediFind in the treatment of Neurotoxicity Syndromes. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Graft, and Bone Marrow Aspiration. Dr. Locke is currently accepting new patients.

Elite in Neurotoxicity Syndromes
Elite in Neurotoxicity Syndromes
Referral may be required
Via Cadore 48, 
Monza, IT 

Paola Alberti practices practicing medicine in Monza, Italy. Ms. Alberti is rated as an Elite expert by MediFind in the treatment of Neurotoxicity Syndromes. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Neurotoxicity Syndromes, Peripheral Neuropathy, Neuralgia, and Colorectal Cancer.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Neurotoxicity Syndromes
Elite in Neurotoxicity Syndromes
Referral may be required
Via Cadore 48, MB, 
Monza, IT 

Guido Cavaletti practices practicing medicine in Monza, Italy. Mr. Cavaletti is rated as an Elite expert by MediFind in the treatment of Neurotoxicity Syndromes. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Peripheral Neuropathy, Neurotoxicity Syndromes, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Polyradiculoneuritis, and Islet Cell Transplantation.

View All Doctors
What are the latest Neurotoxicity Syndromes Clinical Trials?
Network Based Repetitive Transcranial Magnetic Stimulation (rTMS) as an Intervention for Levodopa-induced Dyskinesia (LID) in Parkinson's Disease (PD)
Network Based Repetitive Transcranial Magnetic Stimulation (rTMS) as an Intervention for Levodopa-induced Dyskinesia (LID) in Parkinson's Disease (PD)
Enrollment Status: Recruiting
Publish Date: August 27, 2026
Intervention Type: Device
Study Phase: Not Applicable

Summary: The proposed study investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for levodopa-induced dyskinesia (LID) in Parkinson's Disease (PD). Specifically, the study aims to determine whether patterned stimulation of the pre-supplementary motor area (pre-SMA) can delay the onset of LID after levodopa intake and reduce LID severity in PD patients. This study will ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
IIT2022-04-Sasine-CAR-T: A Phase 1 Single-arm, Open-label Study to Evaluate the Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
IIT2022-04-Sasine-CAR-T: A Phase 1 Single-arm, Open-label Study to Evaluate the Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Enrollment Status: Recruiting
Publish Date: August 10, 2026
Intervention Type: Biological
Study Phase: Phase 1

Summary: The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate feasibility of collecting the target dose of HSCs from at least 50% of enrolled patients. The study will assess safety based on incidence and severity of...

View All Clinical Trials